MedFluid Co., Ltd.
MedFluid commits to be the best weapon for human beings to combat antimicrobial resistance (AMR) as well as Superbug.
MedFluid commits to be the best weapon for human beings to combat antimicrobial resistance (AMR) as well as Superbug.
MedFluid Co., Ltd. is a biotechnology startup founded in 2019 with the commitment to combat antimicrobial resistance and Superbug through innovative biomedical testing. The company leverages patented LOC (Lab-on-a-chip) microfluidics to provide affordable and user-friendly solutions for decentralized healthcare. Their offerings include POCT molecular diagnosis ("O-in") and rapid antimicrobial susceptibility testing ("NAST").
MedFluid's focus on addressing critical healthcare challenges such as antimicrobial resistance positions it within the Biotechnology and Health Care industries. While specific details about the company's headquarters and latest investment are not available at this time, its dedication to tackling pressing global health issues makes it an intriguing prospect for potential venture capital investment.
There is no investment information
No recent news or press coverage available for MedFluid Co., Ltd..
We care about your data, and we'd love to use cookies make your experience better.
